Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 8,611 matching trials from the live ClinicalTrials.gov search.

Filters: Indianapolis, Indiana Clear all

Conditions: Non-Small Cell Lung Cancer
Interventions: ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Loma Linda, California • Indianapolis, Indiana + 4 more

Conditions: Lymphocytic Leukemia, Chronic
Interventions: Obinutuzumab, Corticosteroids; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 24 more

Conditions: Advanced Solid Tumors
Interventions: AMG 650; Drug
Lead sponsor: Volastra Therapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Los Angeles, California • Santa Monica, California • Indianapolis, Indiana + 10 more

Conditions: Advanced Solid Tumors
Interventions: Drug：LM-102; Drug
Lead sponsor: LaNova Medicines Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: California City, California • Indianapolis, Indiana • Detroit, Michigan + 3 more

Conditions: Fuchs' Endothelial Dystrophy, Corneal Edema
Interventions: Endothelial keratoplasty, PRGF; Procedure · Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Indianapolis, Indiana

Conditions: Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions: VLS-1488; Drug
Lead sponsor: Volastra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Interventions: Biospecimen Collection; Procedure
Lead sponsor: PedAL BCU, LLC; Other
Eligibility: Up to 22 Years
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 164
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more

Conditions: Heart Failure
Interventions: Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 34
States / cities: Huntsville, Alabama • Anchorage, Alaska • Redwood City, California + 31 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Buena Park, California • Fresno, California • San Jose, California + 11 more

Conditions: Seizure Disorder, Partial
Interventions: Pregabalin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more

Conditions: Hemophilia B
Interventions: PF-06838435/ fidanacogene elaparvovec; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 16
States / cities: San Francisco, California • Aurora, Colorado • Indianapolis, Indiana + 2 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Interventions: AMG 386, Paclitaxel, AMG 386 Placebo, Carboplatin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,015 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 173
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 142 more

Conditions: Bradycardia
Interventions: Cardiac pacing; Device
Lead sponsor: Duke University; Other
Eligibility: 1 Day and older
Enrollment: 1,383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Sarasota, Florida • Chicago, Illinois • Indianapolis, Indiana + 5 more

Conditions: Osteogenesis Imperfecta
Interventions: Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 13
States / cities: Los Angeles, California • Torrance, California • Aurora, Colorado + 10 more

Conditions: Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions: Droxidopa, Placebo; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 44
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more

Conditions: Surgery
Interventions: IT Injection, ESP Block; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: motesanib diphosphate; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 19
States / cities: Burbank, California • New Britain, Connecticut • Chicago, Illinois + 14 more

Conditions: Rheumatoid Arthritis
Interventions: LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,041 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 75
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 72 more

Conditions: Advanced Malignant Solid Neoplasm, Bile Duct Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer
Interventions: Afatinib Dimaleate, Capecitabine, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 19 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • Seattle, Washington

Conditions: MPN (Myeloproliferative Neoplasms)
Interventions: Pemigatinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 9
States / cities: Phoenix, Arizona • Duarte, California • Stanford, California + 6 more

Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Interventions: Lecanemab, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more

Conditions: Alcohol Use Disorder
Interventions: Guanfacine Extended Release (XR), Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Indianapolis, Indiana • Newark, New Jersey

Conditions: Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
Interventions: Panitumumab, Bevacizumab, mFOLFOX6; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 63
States / cities: Birmingham, Alabama • Huntsville, Alabama • Berkeley, California + 59 more

Conditions: Post-Traumatic Headache
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more

Search by objective public record fields.

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Study of AMG 650 in Adult Participants With Advanced Solid Tumors

Study of LM-102 in Subjects in Advanced Tumors

Plasma Rich in Growth Factors in Corneal Endothelial Transplantation

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)

SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conduction System Pacing With INGEVITY+

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery

AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Guanfacine for Alcohol Use Disorder (AUD)

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)